Reata Pharmaceuticals, Inc. (RETA) Stock Analysis

Reata Pharmaceuticals, Inc. (RETA) Healthcare & Pipeline Overview

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in novel therapeutics for severe diseases, particularly chronic kidney disease and neurological disorders. Their strategic collaborations and focus on Nrf2 activators position them within the competitive biotechnology landscape, targeting unmet medical needs.

What Is the Investment Thesis for RETA?

Reata Pharmaceuticals presents a compelling investment thesis centered on its innovative pipeline and strategic partnerships. The primary value driver is the potential approval and commercialization of bardoxolone for CKD caused by Alport syndrome, a market with significant unmet needs. Positive Phase 3 trial results and regulatory approval could lead to substantial revenue growth. The company's collaboration with Kyowa Kirin and AbbVie provides additional revenue streams and validation of its technology. Key catalysts include upcoming clinical trial readouts for omaveloxolone in Friedreich's ataxia and continued progress in its Phase 2 CKD studies. Potential risks include regulatory hurdles, clinical trial failures, and competition from existing and emerging therapies. With a market capitalization of $6.57B, Reata's valuation reflects the anticipated success of its pipeline and strategic initiatives.

Based on FMP financials and quantitative analysis

RETA Key Highlights

Market Cap of $6.57B reflects investor confidence in Reata's pipeline and potential for future growth.

• Gross Margin of 100.0% indicates strong pricing power and efficient manufacturing processes.
• Developing Phase 3 clinical trial programs for bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome.
• Strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, and other Asian countries.
• Collaboration with AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications.

Who Are RETA's Competitors?

RETA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RETA's Key Strengths?

Innovative Nrf2 activator platform.

• Strong intellectual property portfolio.
• Strategic partnerships with Kyowa Kirin and AbbVie.
• Advanced clinical trial programs.

What Are RETA's Weaknesses?

Reliance on a limited number of key product candidates.

• High research and development costs.
• Dependence on regulatory approvals.
• Negative Profit Margin of -14075.0%.

What Could Drive RETA Stock Higher?

Potential FDA approval of bardoxolone for CKD caused by Alport syndrome (timeline: 2026).

• Clinical trial readouts for omaveloxolone in Friedreich's ataxia (timeline: 2026).
• Progress in Phase 2 studies for various forms of CKD.
• Development of RTA 901 for neurological diseases.
• Development of RTA 1701 for autoimmune, inflammatory, and fibrotic diseases.

What Are the Key Risks for RETA?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Regulatory delays or rejection of bardoxolone for CKD caused by Alport syndrome.
• Clinical trial failures for omaveloxolone or other pipeline candidates.
• Competition from existing and emerging therapies.
• High research and development costs.
• Dependence on strategic partnerships for revenue and market access.

What Are the Growth Opportunities for RETA?

• Expansion into New Therapeutic Areas: Reata has the opportunity to expand its pipeline beyond CKD and Friedreich's ataxia by developing RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory, and fibrotic diseases. These areas represent significant unmet medical needs and large market opportunities. The market size for autoimmune diseases alone is projected to reach $150 billion by 2028. Successful development and commercialization of these therapies could significantly increase Reata's revenue and market share. Timeline: Ongoing, with Phase 1/2 trials expected to commence in the next 12-24 months.
• Geographic Expansion through Partnerships: Reata's strategic collaboration with Kyowa Kirin provides access to key Asian markets, including Japan, China, and South Korea. These markets represent significant growth opportunities for bardoxolone in renal, cardiovascular, diabetes, and related metabolic indications. The prevalence of these diseases is high in Asia, creating a large potential market for Reata's therapies. Timeline: Ongoing, with commercialization efforts expected to ramp up following regulatory approvals in these regions.
• Development of Second-Generation Nrf2 Activators: Reata's collaboration with AbbVie focuses on the development of second-generation Nrf2 activators for indications outside of renal, cardiovascular, and metabolic diseases. This partnership provides access to AbbVie's expertise and resources, accelerating the development of new therapies. The market for Nrf2 activators is expected to grow significantly as more clinical data emerges supporting their efficacy and safety. Timeline: Ongoing, with preclinical and early-stage clinical trials expected to progress over the next 3-5 years.
• Commercialization of Bardoxolone for Alport Syndrome: The potential approval and commercialization of bardoxolone for CKD caused by Alport syndrome represents a significant growth opportunity for Reata. Alport syndrome is a rare genetic disorder that affects the kidneys, and there are currently limited treatment options available. The market for Alport syndrome therapies is estimated to be $500 million to $1 billion annually. Timeline: Near-term, pending regulatory approval based on Phase 3 clinical trial results.
• Expansion into Additional CKD Subtypes: Reata is conducting Phase 2 studies for various forms of CKD, including IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis. These CKD subtypes represent significant unmet medical needs and large market opportunities. Successful development and commercialization of therapies for these subtypes could significantly increase Reata's revenue and market share. Timeline: Mid-term, with Phase 3 trials and potential commercialization expected in the next 3-5 years.

What Are RETA's Competitive Advantages?

• Proprietary Nrf2 Activator Platform: Reata's expertise in developing Nrf2 activators provides a competitive advantage in addressing a wide range of diseases.
• Strong Intellectual Property Portfolio: Reata has patents protecting its key therapeutic compounds and formulations.
• Strategic Partnerships: Collaborations with Kyowa Kirin and AbbVie provide access to key markets and resources.
• Clinical Trial Expertise: Reata has a proven track record of conducting successful clinical trials.
• First-Mover Advantage: Reata is a leader in developing therapies for Alport syndrome and Friedreich's ataxia.

What Does RETA Do?

Reata Pharmaceuticals, Inc., founded in 2002 and headquartered in Plano, Texas, is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies for patients facing serious or life-threatening illnesses. The company's focus is on modulating cellular metabolism and inflammation through the activation of key transcription factors. Reata's lead product candidates include bardoxolone methyl (bardoxolone) and omaveloxolone. Bardoxolone is being developed for chronic kidney disease (CKD) caused by Alport syndrome and pulmonary arterial hypertension associated with connective tissue disease. Omaveloxolone is in Phase II clinical trials for the treatment of Friedreich's ataxia. Additionally, Reata is conducting Phase 2 studies for various forms of CKD, including IgA nephropathy and diabetic CKD. The company is also developing RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory, and fibrotic diseases. Reata collaborates with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone in several Asian markets and with AbbVie Inc. for second-generation Nrf2 activators, excluding renal, cardiovascular, and metabolic indications. Reata's evolution from Reata Discovery, Inc. to its current form reflects its commitment to addressing unmet medical needs through innovative drug development.

What Products and Services Does RETA Offer?

• Develop and commercialize novel therapeutics for serious and life-threatening diseases.
• Focus on modulating cellular metabolism and inflammation through Nrf2 activation.
• Develop bardoxolone methyl (bardoxolone) for chronic kidney disease (CKD) caused by Alport syndrome.
• Develop omaveloxolone for the treatment of Friedreich's ataxia.
• Conduct Phase 2 studies for various forms of CKD, including IgA nephropathy and diabetic CKD.
• Develop RTA 901 for neurological diseases.
• Develop RTA 1701 for autoimmune, inflammatory, and fibrotic diseases.
• Collaborate with Kyowa Kirin and AbbVie to expand the reach of their therapies.

How Does RETA Make Money?

• Develop and patent novel therapeutic compounds.
• Conduct clinical trials to demonstrate the safety and efficacy of their therapies.
• Seek regulatory approval from agencies such as the FDA.
• Commercialize approved therapies directly or through partnerships.
• Generate revenue through product sales and licensing agreements.

What Industry Does RETA Operate In?

Reata Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for CKD therapies is substantial and growing, driven by the increasing prevalence of diabetes and hypertension. Reata's focus on Nrf2 activators positions it within a promising area of drug development, as these molecules have the potential to address a wide range of diseases. Competitors include companies developing therapies for kidney disease, neurological disorders, and autoimmune conditions. The biotechnology industry is expected to continue to grow, driven by advances in genomics, proteomics, and personalized medicine.

Who Are RETA's Key Customers?

• Patients with chronic kidney disease (CKD) caused by Alport syndrome.
• Patients with Friedreich's ataxia.
• Patients with various forms of CKD, including IgA nephropathy and diabetic CKD.
• Healthcare providers who prescribe Reata's therapies.
• Strategic partners such as Kyowa Kirin and AbbVie.

Company Profile

Reata Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Plano, US. The company is led by CEO J. Warren Huff. RETA has traded publicly since 2016.

How Reata Pharmaceuticals, Inc. Is Valued

Reata Pharmaceuticals, Inc. carries a market capitalization of $6.57B, placing it in the mid-cap category.

Return on equity for Reata Pharmaceuticals, Inc. stands at 47.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.0%, the inverse of the P/E and a quick read on earnings relative to price.

Reata Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.37 places it in the safe zone, indicating low near-term bankruptcy risk.

RETA Financials

RETA Latest News

Common Questions About RETA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources